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TRPM7 (transient receptor potential cation channel, sub-family M, member 7) belongs to the melastatin-related 
transient receptor potential subfamily of transient receptor 
potential channels1,2 and forms a constitutively active diva-
lent cation-selective channel that regulates many cellular 
processes, including cell cycle, apoptosis, and cell death.1,3–5 
Global ablation of TRPM7 or deletion of its kinase domain 
results in early embryonic lethality in mice.5,6 In vitro, TRPM7 
deficiency in DT40 cells and also other cell types results in 
the depletion of [Mg2+]
i
 and growth arrest in the presence of 
normal extracellular [Mg2+].1,4 TRPM7-mediated cation influx 
has been detected in megakaryocytes,7 and dysfunction of 
TRPM7 channel, but not its kinase activity, causes macro-
thrombocytopenia in humans and mice because of an imbal-
anced Mg2+ homeostasis in megakaryocytes and platelets.8
See accompanying editorial on page 285
TRPM7 contains a cytosolic α-kinase domain with an 
Mg2+/ATP-binding site, which is critical for the catalytic 
activity, and its mutation on lysine 1646 abolishes the kinase 
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Objective—TRPM7 (transient receptor potential cation channel, subfamily M, member 7) is a ubiquitously expressed bifunctional 
protein comprising a transient receptor potential channel segment linked to a cytosolic α-type serine/threonine protein kinase 
domain. TRPM7 forms a constitutively active Mg2+ and Ca2+ permeable channel, which regulates diverse cellular processes 
in both healthy and diseased conditions, but the physiological role of TRPM7 kinase remains largely unknown.
Approach and Results—Here we show that point mutation in TRPM7 kinase domain deleting the kinase activity in mice 
(Trpm7R/R) causes a marked signaling defect in platelets. Trpm7R/R platelets showed an impaired PIP2 (phosphatidylinositol-
4,5-bisphosphate) metabolism and consequently reduced Ca2+ mobilization in response to stimulation of the major platelet 
receptors GPVI (glycoprotein VI), CLEC-2 (C-type lectin-like receptor), and PAR (protease-activated receptor). Altered 
phosphorylation of Syk (spleen tyrosine kinase) and phospholipase C γ2 and β3 accounted for these global platelet 
activation defects. In addition, direct activation of STIM1 (stromal interaction molecule 1) with thapsigargin revealed a 
defective store-operated Ca2+ entry mechanism in the mutant platelets. These defects translated into an impaired platelet 
aggregate formation under flow and protection of the mice from arterial thrombosis and ischemic stroke in vivo.
Conclusions—Our results identify TRPM7 kinase as a key modulator of phospholipase C signaling and store-operated 
Ca2+ entry in platelets. The protection of Trpm7R/R mice from acute ischemic disease without developing intracranial 
hemorrhage indicates that TRPM7 kinase might be a promising antithrombotic target.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38: 
344-352. DOI: 10.1161/ATVBAHA.117.310391.)
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activity.4,9 Autophosphorylation of the TRPM7 kinase domain 
on serine 1511/1567 enhances kinase–substrate interac-
tions leading to their serine/threonine phosphorylation.10–13 
Although it has been demonstrated that the kinase domain 
of TRPM7 directly binds PLC (phospholipase C) isoforms,14 
contradictory findings exist on the functional consequence of 
this interaction. Depending on the used heterologous expres-
sion system in vitro, GPCR (G-protein–coupled receptor)-
mediated PLCβ activation can either positively or negatively 
modulate TRPM7 channel activity.14–16 Recently, it has been 
shown that PLCγ2—an important regulator of immunorecep-
tor tyrosine-based activation motif (ITAM) receptor-mediated 
Ca2+ signaling—is phosphorylated by TRPM7 kinase17; how-
ever, the physiological significance of this modification is not 
fully understood. PLC-mediated PIP2 (phosphatidylinositol 
4,5-bisphosphate) hydrolysis induces Ca2+ store depletion 
thereby enhancing store-operated Ca2+ entry (SOCE), which 
is regulated by functional coupling of the Ca2+ sensor STIM1 
(stromal interaction molecule 1) and the Ca2+ channel Orai1 
in mammalian nucleated cells and platelets.18 Recent reports 
provided in vitro evidence that TRPM7 kinase regulates Ca2+ 
store content, STIM1 function, and SOCE in chicken B cells.19
It has been reported that mice subjected to the transient 
middle cerebral artery occlusion (tMCAO) model of ischemic 
stroke display an upregulation of TRPM7 protein expression 
in neurons. In contrast, downregulation of TRPM7 in the isch-
emic brain prevented neuronal necrosis.20,21 Consequently, it 
was speculated that the increased TRPM7 channel activity 
may enhance Ca2+ influx and induce neuronal cell death in 
the ischemic brain.22 However, the role of TRPM7 kinase 
domain in the process of thromboinflammation and stroke 
and the associated signaling pathways remain elusive.
Here we show that deletion of the TRPM7 kinase activ-
ity in mice (Trpm7R/R) inhibits (hem)ITAM-PLCγ2 and PAR 
(protease-activated receptor)-PLCβ3–mediated intracellular 
Ca2+ mobilization, and partially blocks SOCE in platelets, 
resulting in protection of mice from arterial thrombosis and 
thromboinflammatory brain infarction in a model of ischemic 
stroke.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Mg2+ Homeostasis and TRPM7 Channel Activity 
in Kinase-Dead TRPM7 Knock-In Mice
Recently, we identified TRPM7 as a key regulator of Mg2+ 
homeostasis in megakaryocytes, which is critical for platelet 
biogenesis in the bone marrow (BM).8 To dissect the role of 
TRPM7 kinase and channel function in vivo, a kinase-dead 
knock-in mouse strain was generated (Trpm7R/R) carrying 
a point mutation (Lys1646 to Arg) in the Mg2+ ATP-binding 
site of the kinase domain (Figure IA in the online-only Data 
Supplement). In agreement with a recent report,9 the Lys1646 
mutation of TRPM7 kinase did not influence its channel activ-
ity in mouse embryonic fibroblast cells derived from wild-
type (WT) and Trpm7R/R embryos (Figure IB in the online-only 
Data Supplement). Trpm7R/R mutant mice did not show any 
signs of imbalanced Mg2+ homeostasis because Mg2+ concen-
trations in the blood serum, bones, and platelets were unaltered 
(Figure IC in the online-only Data Supplement). Homozygous 
Trpm7R/R mice were born at a normal Mendelian distribution 
and developed normally. Histological analysis of different 
organs from Trpm7R/R mice revealed no obvious alterations 
(Figure ID in the online-only Data Supplement), and there 
was no evidence for a role of TRPM7 kinase in platelet bio-
genesis because platelet size, number, and morphology,8 as 
well as the expression of major platelet glycoprotein recep-
tors, including GPVI (glycoprotein VI) and CLEC-2 (C-type 
lectin-like receptor), and platelet life span, were indistinguish-
able from controls (Figure IIA and IIB in the online-only Data 
Supplement).
TRPM7 Kinase Regulates (hem)ITAM and 
PAR Receptor-Mediated Ca2+ Store Depletion 
and Is Directly Involved in SOCE
To study the functional significance of TRPM7 kinase in plate-
lets, agonist-induced inside-out activation of integrin αIIbβ3 
and P-selectin surface exposure, as a marker of α-granule 
release, were assessed by flow cytometry. Activation of 
Trpm7R/R platelets was significantly reduced in response to 
intermediate or low doses of thrombin and GPVI-specific 
agonists (collagen-related peptide [CRP], convulxin [CVX]; 
Figure 1A). However, Trpm7R/R platelets were able to spread 
on fibrinogen with similar kinetics as WT control platelets, 
indicating that TRPM7 kinase did not affect integrin outside-
in signaling (Figure IIC in the online-only Data Supplement). 
Aggregation responses of Trpm7R/R platelets to high concen-
trations of either GPVI or GPCR agonists (U46619, ADP, 
Nonstandard Abbreviations and Acronyms






ITAM immunoreceptor tyrosine-based activation motif
LAT linker for activation of T cells
PAR protease-activated receptor
PECAM platelet-endothelial cell adhesion molecule
PIP2 phosphatidylinositol-4, 5-bisphosphate
PKC protein kinase C
PKCϵ protein kinase C epsilon type
PLC phospholipase C
SOCE store-operated Ca2+ entry
STIM1 stromal interaction molecule 1
Syk spleen tyrosine kinase
tMCAO transient middle cerebral artery occlusion
TP thromboxane receptor
TRPM7 transient receptor potential cation channel, subfamily M, 
member 7
WT wild type
346  Arterioscler Thromb Vasc Biol  February 2018
thrombin) or arachidonic acid were normal. However, at 
threshold concentration of CRP, collagen, and thrombin, 
the aggregation response was impaired in Trpm7R/R platelets 
(Figure 1B). Amplification of GPVI signaling requires acti-
vation of the linker for activation of T cells (LAT) complex 
through spleen tyrosine kinase (Syk), as well as thromboxane 
A2 and ATP/serotonin release. We found that pretreatment 
with the Syk inhibitor BI1002494 could mimic the aggrega-
tion defects of Trpm7R/R platelets in response to GPVI agonists, 
whereas the TP (thromboxane receptor) blocker SQ29548 had 
no effect. In contrast, thrombin-dependent aggregation was 
normalized in the presence of SQ29548 (Figure 1B and 1C). 
Moreover, thrombin or CRP-mediated serotonin and ATP 
release from δ-granules was significantly reduced in Trpm7R/R 
platelets at threshold agonist concentrations, whereas throm-
boxane A2 release was not affected (Figure 2A; Figure IID 
in the online-only Data Supplement). In line with this result, 
pretreatment with a high dose of apyrase or supplementation 
of ADP normalized collagen-mediated aggregation responses 
of Trpm7R/R platelets (Figure IIIA in the online-only Data 
Supplement). Altogether, these results suggest that TRPM7 
kinase is specifically involved in granule release but not in the 
direct activation of TP receptor or thromboxane A2 synthesis.
Activation-dependent increase in cytoplasmic Ca2+ con-
centrations ([Ca2+]
i
) through the release of Ca2+ from intra-
cellular stores and subsequent SOCE and receptor-operated 
Ca2+ entry are prerequisites for platelet integrin αIIbβ3 acti-
vation, as well as degranulation.18,23 To investigate whether 
altered Ca2+ responses accounted for the impaired α- and 
δ-granule secretion in Trpm7R/R platelets, GPVI-ITAM and 
GPCR signaling were analyzed by fluorimetric determination 
of agonist-induced changes in [Ca2+]
i
. In line with the reduced 
integrin activation and degranulation, Ca2+-store release was 
significantly reduced in Trpm7R/R platelets in response to 
CRP or thrombin (Figure 2B), indicating a combined GPVI 
and PAR receptor signaling defect on platelet activation. As 
a consequence of the abnormal Ca2+ store release, the GPVI-
PLCγ2– and thrombin-PLCβ–induced Ca2+ influx was also 
reduced in Trpm7R/R platelets and could be normalized by 
treatment with BI1002494 (Figure 2C). To study whether 
Figure 1. Defective platelet activation and 
aggregation responses in Trpm7R/R mice. 
A, Flow cytometric analysis of αIIbβ3 
activation (top) and P-selectin exposure 
(bottom) in WT (black bars) and Trpm7R/R 
(grey bars) platelets. Concentrations of 
agonists are indicated. Results are pre-
sented as mean fluorescence intensity 
(MFI)±SD. B–D, Aggregation curves of 
WT (black) and Trpm7R/R (grey) platelets in 
response to the indicated agonists with 
or without the stated treatments. Washed 
platelets were stirred for indicated time 
in the presence of the indicated agonists, 
and light transmission was recorded with 
an aggregometer. ADP measurements 
were performed in platelet-rich plasma 
(PRP). U46, stable thromboxane A2 ana-
logue U46619. BI1002494, Syk blocker; 
SQ29548, TP receptor blocker. Unpaired 
Student t test *P<0.05, **P<0.01, 
***P<0.001. AA indicates arachidonic 
acid; Coll, Horm collagen; CRP, collagen-
related peptide; Ctrl, control; CVX, con-
vulxin; and Thr, thrombin.
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TRPM7 kinase could directly contribute to the regulation of 
SOCE, the sarco/endoplasmic reticulum Ca2+ ATPase inhibi-
tor thapsigargin was used to bypass the GPVI- and PAR recep-
tor-induced Ca2+ mobilization defect and directly modulate 
SOCE. Despite the normal basal cytoplasmic Ca2+ level and 
thapsigargin-induced Ca2+ store release, SOCE was strongly 
reduced in Trpm7R/R platelets, suggesting a specific role of 
TRPM7 kinase in the regulation of STIM1-mediated SOCE in 
platelets (Figure 2Di).
GPVI and PAR receptor signaling involves a series of 
phosphorylation events that finally enhance PLCγ2 and PLCβ 
activity, respectively, which mediates the hydrolysis of PIP
2
 
into inositol triphosphate (IP
3
) and diacylglycerol.23,24 IP
3
-




 receptors) on intra-
cellular Ca2+ store membranes leads to their activation and 
subsequent Ca2+ store depletion. Because both GPVI and 
PAR receptor-induced Ca2+ store depletion were abnormal in 
Trpm7R/R platelets, and the kinase domain of TRPM7 directly 
binds PLC isoforms,14 IP
3
 concentrations in activated platelets 
were determined with an indirect method using an IP
1
 ELISA. 
In line with the other results, IP
1
 production in response to 
CRP and low dose of thrombin were reduced in Trpm7R/R 
platelets, indicating a defective PIP
2
 metabolism in Trpm7R/R 
platelets (Figure 2Dii).
The GPVI signalosome is regulated by Src family kinase 
Lyn and the tyrosine kinase Syk, which modulates the enzy-
matic activity of PLCγ2 and other signaling molecules.25 In 
agreement with our previous results (Figures 1B, 2B, and 
2C), we found delayed tyrosine phosphorylation of SykY525/526, 
LATY132/Y191, and PLCγ2Y759 in Trpm7R/R platelets upon 
low-dose CRP stimulation, whereas the phosphorylation was 
normal at high-dose CRP stimulation (Figure 3A; Figure IIIB 
in the online-only Data Supplement). Furthermore, phosphor-
ylation of serine residue 729 on PKCϵ (PKC [protein kinase 
C] epsilon type)—a downstream effector of PLCγ2—was also 
diminished. In sharp contrast, phosphorylation of LynY507 at 
the inhibitory loop of the enzyme was unaltered (Figure 3A). 
Based on these findings, we hypothesized that a proximal regu-
lator, such as Syk, could be affected in Trpm7R/R platelets. In 
addition, PLCβ3 phosphorylation was also reduced upon stim-
ulation with different concentrations of thrombin (Figure 3B; 
Figure IIIC in the online-only Data Supplement). To further 
address the potential role of Syk in TRPM7 kinase signaling, 
(hem)ITAM receptor CLEC-2 was stimulated with rhodocy-
tin. Integrin activation, P-selectin exposure, and aggregation 
responses of Trpm7R/R platelets toward high concentrations 
of rohdocytin were normal, whereas activation responses to 
intermediate and lower agonist concentrations were reduced 
(Figure 4A and 4B). In line with this, we observed a reduced 
phosphorylation of SykY525/526, LATY132/Y191, and PLCγ2Y759 in 
Trpm7R/R platelets upon rohdocytin stimulation (Figure 4C).
TRPM7 Kinase Is Essential for Occlusive 
Arterial Thrombus Formation
To study whether TRPM7-mediated modulation of PLCγ2 
activity plays a significant regulatory role in thrombosis and 
hemostasis, we next analyzed the ability of Trpm7R/R platelets 
to form thrombi on fibrous collagen in a heparinized whole 
Figure 2. Reduced serotonin release, ATP 
release, Ca2+ responses, and phospho-
lipase C activity in Trpm7R/R platelets. A, 
Measurement of platelet-released sero-
tonin in both resting (Rest) and activated 
states tested by ELISA (left). Platelets 
were activated with the indicated ago-
nists, and ATP secretion was determined 
(right). B, Ca2+ responses were mea-
sured in Fura-2-loaded platelets for store 
release. C, Ca2+ responses were mea-
sured in Fura-2-loaded platelets in the 
presence of Ca2+ for Ca2+ entry. (Di) Thap-
sigargin (TG)-induced Ca2+ responses 
were measured for store release (left) and 
store-operated Ca2+ entry (SOCE; right). 
Mean increase in [Ca2+]i quantified by 
subtracting baseline levels before stimu-
lus and finally (Δ[Ca2+]i)±SD is reported. 
Triton-X for maximal and EDTA for mini-
mal calcium levels were used to calibrate 
each measurement. (Dii) IP1 (inositol 
monophosphate) production, as a spe-
cific metabolite of IP3, was quantified on 
activation with the indicated concentra-
tions of either collagen-related peptide 
(CRP) or thrombin (Thr; right). WT (black 
bars) and Trpm7R/R (grey bars). Unpaired 
Student t test *P<0.05, **P<0.01, 
***P<0.001. BI, Syk blocker BI1002494.
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blood perfusion system to prevent thrombin generation. 
Here, WT platelets adhered to the collagen fibers and formed 
3-dimensional aggregates within 2 to 4 minutes, which con-
sistently grew resulting in large thrombi at the end of the per-
fusion period, whereas Trpm7R/R platelets exhibited reduced 
adhesion and impaired formation of 3-dimensional thrombi 
(Figure 5A). To test whether these defects also translated into 
impaired arterial thrombosis in vivo, we induced a mechanical 
injury on the abdominal aorta and then monitored blood flow 
with an ultrasonic flow probe. Although in WT mice, 19 of 21 
(90%) arteries occluded during the observation period, only 
11 of 19 (58%) Trpm7R/R arteries formed occlusive thrombi, 
and these showed significantly prolonged occlusion times 
compared with WT control (WT, 297±89 versus Trpm7R/R, 
454±189 s; Figure 5B). Next, thrombus formation was induced 
by injuring mesenteric arterioles with FeCl
3
 and thrombus for-
mation was monitored by intravital fluorescence microscopy. 
The time to first appearance of thrombi <10 µm was similar 
in the mesenteric arterioles of WT and Trpm7R/R mice (WT, 
506±95 versus Trpm7R/R, 528±117 s; Figure IV in the online-
only Data Supplement). In sharp contrast, although complete 
vessel occlusion was observed in all arteries of WT mice, 15 
of 26 (58%) vessels in Trpm7R/R mice did not occlude (mean 
time to occlusion: WT, 966±234 versus Trpm7R/R, 1236±339 
s; Figure 5C, left; Movies I and II in the online-only Data 
Supplement). This defect seemed to result from thrombus 
instability because microaggregates were frequently released 
from the surface of Trpm7R/R thrombi. Furthermore, Trpm7R/R 
mice were fully protected in a third thrombosis model, where 
thrombus formation was induced in the carotid arteries by 
topical application of FeCl
3
 and blood flow is monitored by 
an ultrasonic flow probe (Figure 5C, right). Besides defective 
arterial thrombus formation, we also observed a prolonged tail 
bleeding time in Trpm7R/R mice (mean bleeding time of WT, 
338±261 versus Trpm7R/R, 638±332 s; Figure 5D), demon-
strating an important role of TRPM7 kinase in primary hemo-
stasis. These findings revealed that TRPM7 kinase-dependent 
modulation of GPVI signaling is a critical determinant for 
thrombus growth and stability in vivo.
TRPM7 Kinase Plays an Important 
Role in Ischemic Stroke
To assess a possible functional role of TRPM7 kinase in the 
pathogenesis of acute ischemic brain infarction, we next ana-
lyzed neuronal damage in WT and Trpm7R/R mice subjected 
to tMCAO. In this model of ischemic stroke, a filament is 
advanced to the middle cerebral artery to occlude the vessel 
for 1 hour followed by reperfusion after removal of the fila-
ment, which typically results in further infarct growth during 
the next 24 hours (reperfusion injury).26 Strikingly, infarct 
volumes in Trpm7R/R brains after 24 hours were dramatically 
reduced to <40% of those seen in WT controls (Figure 6A). 
To determine whether this protective effect was because of 
an increased resistance of Trpm7R/R neurons to ischemia or to 
altered blood cell function, BM chimeras were generated by 
injecting WT BM cells into lethally irradiated Trpm7R/R mice 
and vice versa. Remarkably, both, Trpm7R/R animals substituted 
with WT BM and WT animals substituted with Trpm7R/R BM 
cells developed significantly smaller infarcts compared with 
WT animals that received WT BM cells (WT/BMWT, 97±22 
versus Trpm7R/R/BMWT, 47±11 versus WT/BMTrpm7R/R, 59±35 
mm3; ***P=0.001; Figure 6B, left). Importantly, in serial mag-
netic resonance imaging on day 7 after tMCAO, we did not 
observe delayed infarct progression or intracranial hemorrhage 
(Figure 6B, right). The reduction in infarct size was function-
ally relevant because global neurological (Bederson score) 
and motor (Grip test) functions (Figure 6C) were improved in 
Trpm7R/R/BMWT and WT/BMTrpm7R/R mice, when compared with 
WT mice 1 day after tMCAO. Infarct growth in the acutely 
ischemic brain involves closely intertwined inflammatory and 
thrombotic pathomechanisms, referred to as thromboinflam-
mation, in which platelets are key mediators.27 To further 
clarify the extent to which altered platelet function contributed 
to the protection of WT/BMTrpm7R/R mice from tMCAO-induced 
neuronal damage, WT mice rendered thrombocytopenic by 
anti-GPIbα (glycoprotein Ib alpha) antibody injection were 
transfused with WT or Trpm7R/R platelets and subsequently sub-
jected to tMCAO.28,29 Remarkably, WT mice that had received 
Trpm7R/R platelets developed significantly smaller brain 
infarcts compared with controls, and also global neurological 
and motor function were significantly improved (Figure 6D), 
Figure 3. TRPM7 (transient receptor potential cation channel, sub-
family M, member 7) kinase phosphorylates and regulates GPVI- 
and PAR-mediated signaling. A, Western blot showing the tyrosine 
phosphorylation pattern of Trpm7R/R platelets on collagen-related 
peptide (CRP) or (B) thrombin (Thr) stimulation. LAT indicates 
linker for activation of T cells; PKCϵ, protein kinase C epsilon type; 
PLCγ2, phospholipase C γ2; and Syk, spleen tyrosine kinase.
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clearly demonstrating that TRPM7 kinase activity in platelets 
contributes to the development of ischemic brain infarction.
Discussion
The α-kinase protein family comprises various members 
including TRPM6,30 TRPM7,31 and eEF2 serine/threonine 
kinases.32 To date, only few substrates of TRPM7 kinase have 
been identified in vitro, namely myosin IIa,33 PLCγ2,17 and 
annexin-1.12 Although tyrosine kinase-dependent platelet sig-
naling has been extensively studied, the physiological impor-
tance of serine/threonine phosphorylation in ITAM receptor 
signaling triggered by TPRM7 kinase or other α-kinases is 
entirely unknown. The GPVI signalosome is regulated by Src 
family kinases, which bind the cytoplasmic tail of GPVI,34 
Figure 4. TRPM7 (transient receptor 
potential cation channel, subfamily M, 
member 7) kinase phosphorylates and 
regulates CLEC-2 signaling in platelets. 
A, Flow cytometric analysis of αIIbβ3 
activation (top) and P-selectin exposure 
(bottom) in WT (black bars) and Trpm7R/R 
(grey bars) platelets on rhodocytin (RC) 
stimulation. Results are presented as 
mean fluorescence intensity (MFI)±SD. 
B, Aggregation curves of WT (black) and 
Trpm7R/R (grey) platelets in response to 
RC stimulation presented. C, Western 
blot showing the tyrosine phosphorylation 
pattern of Trpm7R/R platelets on RC stimu-
lation. Unpaired Student t test **P<0.01, 
***P<0.001. LAT indicates linker for acti-
vation of T cells; PLCγ2, phospholipase 
C γ2; Rest, resting; and Syk, spleen tyro-
sine kinase.
Figure 5. Impaired thrombus formation in Trpm7R/R mice. A, Heparinized whole blood from WT (black bars) and Trpm7R/R (grey bars) mice was 
perfused over immobilized collagen at a shear rate of 1000 s−1. Left, representative phase-contrast images and fluorescent images (anti-GPIX-
DyLight-488; bottom) are shown. Right, relative thrombus volume (TV) and mean surface coverage±SD (left) of WT (black) and Trpm7R/R (grey) 
are shown. B, The abdominal aorta in WT and Trpm7R/R mice was injured by tight compression with forceps, and blood flow was monitored for 
30 min with an ultrasonic flow probe. The time to stable vessel occlusion is shown. C, Thrombus formation in FeCl3-injured mesenteric arte-
rioles was monitored by intravital microscopy of fluorescently labeled platelets. Time to stable vessel occlusion is shown (left), and thrombus 
formation in FeCl3-injured carotid arteries (right) is presented. D, Tail bleeding times shown in WT and Trpm7
R/R mice. Each symbol represents 
1 individual or 1 mesenteric arteriole. Fisher exact test for assessment of differences between open and occluded vessels and Student t test 
for the comparison of mean occlusion times were used. *P<0.05, **P<0.01, ***P<0.001. IFI indicates integrated fluorescence intensity.
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and are critical for initial activation of the GPVI signalosome. 
However, they can also inhibit platelet activation through phos-
phorylation of immunoreceptor tyrosine-based inhibition motifs 
on PECAM (platelet-endothelial cell adhesion molecule)-1 and 
modulation of PKC activity.35,36 The tyrosine kinase Syk trans-
duces the signal from the GPVI/FcRγ (Fc receptor gamma)-
chain to LAT, which in turn induces the recruitment of different 
adaptors and PLCγ2 from the cytosol. It has been shown that 
several PLC isoforms can directly bind the kinase domain of 
TRPM7, and that PLCγ2 is phosphorylated by TRPM7 kinase, 
but the physiological in vivo relevance of these interactions 
remained elusive.2,14,17 Our study now demonstrates that abla-
tion of TRPM7 kinase activity strongly inhibited the tyrosine 
phosphorylation cascade downstream of GPVI and CLEC-2 
involving the Syk-LAT- PLCγ2 signaling axis. Because pre-
treatment of Trpm7R/R platelets with Syk inhibitor BI1002494 
normalized aggregation responses, we speculate that TPRM7 
kinase indeed regulates Syk or upstream effectors in the (hem)
ITAM signaling complex. In addition, PLCβ3 activity is regu-
lated by TRPM7 kinase, which suggests an essential role for 
PLC-mediated Ca2+ store depletion during platelet activation.
It has been shown that several phosphorylation events on 
serine residues of STIM1 are involved in the modulation of 
SOCE37; however, this mechanism and the regulatory kinases 
have not been investigated in platelets. Recently, using het-
erologous expression in DT40 cells, it has been shown that 
TRPM7 regulates SOCE. Furthermore, Ca2+ store content 
and the refilling process of the Ca2+ store are also regulated 
by TRPM7, indicating a functional link between TRPM7 
and STIM1. In line with this, we show in vivo that TRPM7 
kinase activity indeed regulates SOCE in platelets. However, 
further investigation is required to establish the exact molecu-
lar mechanisms by which the channel and kinase domain of 
TRPM7 regulate STIM1-mediated SOCE.
TRPM7 has been shown to be expressed in the human vas-
cular system and to modulate Mg2+ homeostasis, cell growth, 
and proliferation in vascular smooth muscle and endothelial 
cells38 and abnormal expression of the channel has been linked 
to the development of cardiovascular diseases.39 In the pres-
ent study, we demonstrate that the kinase activity of TRPM7 
regulates platelet activation in primary hemostasis and arte-
rial thrombosis, establishing the TRPM7 kinase as a potential 
target to modulate platelet activity in thromboinflammatory 
disease settings. Our results suggest that the combined GPVI 
signaling defects and reduced SOCE account for the thrombus 
instability and antithrombotic protection of Trpm7R/R mice.
Moreover, a balanced Ca2+ and Mg2+ homeostasis plays a 
pivotal role in neuronal survival under ischemic conditions. 
Indeed, Mg2+ was found to be a potent Ca2+ antagonist thereby 
protecting ischemic neurons from Ca2+ overload.40 In sup-
port of this, a reduced intracellular Mg2+ concentration was 
detected in the infarcted rat and human brain, and conversely 
experimental hypomagnesaemia resulted in increased infarct 
volumes after photothrombosis.41–43 Using BM chimeras and 
adoptive platelet transfer, we could decipher the contribution 
of TRPM7 kinase function in platelets from its function in 
endothelial cells and neurons. The improved motor function 
and reduced infarct volumes in Trpm7R/R/BMWT mice clearly 
showed that besides platelets, TRPM7 kinase activity in brain 
tissue, most likely in neurons and glia cells, may also be a crit-
ical factor for the progression of ischemic brain infarction.20 
Interestingly, in WT mice subjected to tMCAO, a 2-to-3–fold 
increase in TRPM7 expression has been observed in the cortex 
after reperfusion,44,45 which likely resulted in a Ca2+ overload 
and contributed to neuronal death, as well as infarct progres-
sion.46 In support of this, knockdown of TRPM7 prevented 
neuronal cell death under ischemic conditions in vivo.21 Based 
on these tMCAO studies, inhibition of TRPM7 channel activ-
ity was proposed as a promising potential therapeutic target.47 
Surprisingly, our results showed that disruption of TRPM7 
kinase activity either in platelets or in neurons is sufficient 
to protect the brain from the thromboinflammatory cerebral 
Figure 6. Trpm7R/R mice are protected from 
cerebral ischemia. A, Representative images 
of 3 corresponding coronal sections of WT and 
Trpm7R/R mice stained with 2,3,5-triphenyltet-
razolium chloride (TTC) 24 h after tMCAO (left). 
Brain infarct volume (IV) in WT and Trpm7R/R 
mice is shown (right). B, IV of bone marrow 
(BM) chimeric mice. WT mice transplanted 
with either WT BM (WT/BMWT) or Trpm7R/R mice 
transplanted with WT BM (Trpm7R/R/BMWT) or 
WT with Trpm7R/R BM (WT/BMTrpm7R/R; left). 
Intracranial hemorrhage was assessed 7 d 
post-tMCAO using serial magnetic resonance 
imaging in the ischemic area (right). C, Neu-
rological outcome studied by Bederson score 
(BS) and Grip test in WT and Trpm7R/R BM 
chimeric mice 24 h post-tMACO. D, Brain IVs 
and functional outcome (left) 24 h after tMCAO 
in platelet-depleted WT mice, reconstituted 
with either WT or Trpm7R/R platelets (WT/PltWT: 
platelet-depleted WT mice transfused with WT 
platelets; WT/PltTrpm7R/R: platelet-depleted WT 
mice transfused with Trpm7R/R platelets). Each 
symbol represents 1 animal. Unpaired Student t 
test or Mann–Whitney U test (BS and grip test) 
*P<0.05, **P<0.01, ***P<0.001.
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I/R injury. These results suggest that under pathological con-
ditions, increased TRPM7 channel activity cannot overcome 
the protective effect of abolished TRPM7 kinase function in 
Trpm7R/R mice. Consequently, we conclude that TRPM7 kinase 
activity, which further accelerates PLC-mediated Ca2+ mobi-
lization and SOCE, rather than enhanced TRPM7 channel 
activity, plays a dominant role in the development of stroke. 
The finding that selective disruption of TRPM7 kinase func-
tion does not cause intracranial bleeding in the ischemic brain 
and only moderately influences hemostasis in mice highlights 
TRPM7 kinase as a potential therapeutic target to develop safe 
antithrombotic or anti-thromboinflammatory agents.
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Highlights
• TRPM7 (transient receptor potential cation channel, subfamily M, member 7) kinase regulates GPVI (glycoprotein VI), CLEC-2 (C-type lectin-
like receptor), and PAR (protease-activated receptor)-mediated signaling through phospholipase C activation and store-operated Ca2+ entry.
• Because of the impaired platelet reactivity, Trpm7R/R mice were protected in different models of arterial thrombosis and in the transient middle 
cerebral artery occlusion model of ischemic stroke.
